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TB elimination: a dream or a
reality? Key lessons from the ERS
external course in Dubrovnik,
Croatia
Tuberculosis (TB) is one of the most
important causes of death among infec-
tious diseases, alongside with HIV/AIDS
and malaria, despite the existence of a
cost-effective strategy for its clinical man-
agement, prevention and control. TB elim-
ination represents a crucial public health
goal, which can be obtained by reducing the
prevalence of individuals with latent TB
infection, through a preventive therapeutic
approach. By reducing the large pool of
infected individuals, global TB incidence
will be decreased and the target of TB
elimination will be achieved by the year
2050, as advocated by the Millennium
Development Goals and the Stop TB
Partnership.
In mid-2013, the European Respiratory
Society (ERS), in association with the FP7 EU-
funded TB-PAN-NET project, ran an unique
course on TB elimination, entitled ‘‘TB
elimination: a dream or reality?’’, in
Dubrovnik, Croatia. The course was attended
by 35 participants who had the chance to
discuss crucial topics on TB elimination with
a faculty of 10 people from the ERS, the
World Health Organization (WHO) and the
American Thoracic Society.
During the discussion among participants
and faculty, five points of interest were
particularly developed.
1. Epidemiological features
helpful for eradication
strategies
The faculty and participants described the
current epidemiological scenario. Estimates
of the burden of disease, as well as that of
latent TB infection (LTBI), were shown. The
pros and cons of the current WHO strategy
were discussed, focusing on potential solu-
tions in the different WHO regions. The
current rate of decline in global TB disease
incidence, based on Bacille Calmette Guerin
(BCG) vaccination as well as treatment of TB
disease and of LTBI, will not allow the
achievement of global elimination by 2050.
It will be important to scale up the WHO’s
public health strategies, as well as to improve
surveillance activities worldwide.
N Suggested article: Dye C, Glaziou P, Floyd K,
et al. Prospects for tuberculosis elimination.
Annu Rev Public Health 2013; 34: 271–286.
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2. New drugs for LTBI and
TB disease
Several presentations explained the main
principles of the design of the experimental
studies currently used to evaluate new
drugs. The methodology used by phar-
maceutical companies was evaluated, using
practical examples. The participants were
actively involved and prepared protocols to
submit to the regulatory agencies to test
their new skills.
In particular, the role of new study
designs (i.e., adaptive trials) which can
enable the evaluation of the safety and
efficacy profile of several drugs, was dis-
cussed. During the discussion, it was
pointed out that clinical and epidemiological
analysis of individuals with comorbidities
(mainly those with TB/HIV co-infection),
and of those in early and advanced
phases of their life, is crucial in evaluating
drugs’ utility.
N Suggested article: Wallis RS. Sustainable
tuberculosis drug development. Clin Infect
Dis 2013; 56: 106–113.
3. New diagnostics for LTBI
and TB disease
The same approach adopted for the
drug section was used to discuss diag-
nostics, pointing out current resources
and new research paths towards innovative
tools.
It is necessary to use an evidence-based
approach to identify the best diagnostic
method; unfortunately, there are several
economic, political and technical issues
that hinder the research and development
into diagnostic innovations. One of the
most relevant difficulties in the devel-
opment of diagnostic methods for LTBI
and TB disease is the lack of a validated
surrogate marker; new genetic methods
seem promising.
N Suggested article: Wallis RS, Kim P, Cole S,
et al. Tuberculosis biomarkers discovery:
developments, needs and challenges.
Lancet Infect Dis 2013; 13: 362–372.
4. Clinical management of
LTBI and TB disease
The faculty prepared electronic materials to
describe the shortcomings of the treatment
regimens currently prescribed for TB disease
and LTBI. Numerous examples drawn from
current practice were used to describe the
correct clinical approach in the management
of Mycobacterium tuberculosis infection. The
recent evidence-based WHO guidelines repre-
sent an important clinical tool to manage
difficult cases; it is crucial to prescribe a
therapeutic combination tailored using drug
susceptibility tests (DST) in order to avoid
the emergence of further resistance.
N Suggested article: Falzon D, Jaramillo E,
Schu¨nemann HJ, et al. WHO guidelines for
the programmatic management of drug-
resistant tuberculosis: 2011 update. Eur
Respir J 2011; 38: 516–528.
5. Research priorities
The last day of the course was dedicated to
future possibilities for medical and non-
medical specialties in global TB elimination.
TB represents a major, immediate public
health problem that should be treated stra-
tegically with the involvement of stakeholders
from a range of fields, taking in specialists in
political affairs, public health, pulmonary
medicine, infectious diseases, social medi-
cine, statistics, etc., as well as partners such
as the pharmaceutical industry.
New training and educational needs are
likely to be identified in the near future and
could be filled in by the ERS. New initiatives
should be focused on the clinical manage-
ment of difficult-to-treat cases as well as on
public health activities to be implemented at
national and sub-national levels.
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